诚信认证：
工商注册信息已核实！
TAK-901
| 品牌 | 厂商性质 | 产地 | 货期 |
|---|---|---|---|
| 阿拉丁 | 生产商 | 上海 | 现货 |
| 货号 | CAS号 | 操作 |
|---|---|---|
| T126322-10mg | 934541-31-8 | 询价 |
| T126322-1mg | 934541-31-8 | 询价 |
| T126322-50mg | 934541-31-8 | 询价 |
| T126322-5mg | 934541-31-8 | 询价 |
- 分子式 C28H32N4O3S
- 分子量504.66
属性
| 溶解性 |
|
| 存贮条件 | 储存温度-20°C |
描述
| 备注 | TAK-901 is a novel inhibitor of Aurora A/B with IC50 of 21 nM/15 nM. It is not a potent inhibitor of cellular JAK2, c-Src or Abl. Phase 1. |
| 生化机理 |
TAK-901 is a small-molecule inhibitor of the serine-threonine kinase Aurora B with potential antineoplastic activity. Aurora B is a positive regulator of mitosis that functions in the attachment of the mitotic spindle to the centromere. This serine/threonine kinase may be amplified and overexpressed by a variety of cancer cell types. After binding of TAK-901 to Aurora B, it inhibits the activity of Aurora B, which may result in a reduction in the proliferation of tumor cells that overexpress Aurora B. TAK-901 is originally developed by Millennium Pharmaceuticals, Inc.. And TAK-901 is been performed phase I clinical trials for the treatment of advanced solid tumors and lymphoma. |
| 别名 | 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide;5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide |
TAK-901信息由上海阿拉丁生化科技股份有限公司为您提供，如您想了解更多关于TAK-901报价、型号、参数等信息，欢迎来电或留言咨询。
注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途